Common Drug Review
Results 1 - 296 of 296
-
Abacavir / lamivudine
Brand name Kivexa Manufacturer GlaxoSmithKline Indication HIV infection Submission type Initial Project Number S0038 Date submission received 2005-07-26 Status Complete Submission status report Date recommendation issued 2005-12-07 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Abatacept
Brand name Orencia Manufacturer Bristol-Myers Squibb Canada Indication Arthritis, Rheumatoid Submission type Pre-NOC Project Number SR0299 Date submission received 2012-11-29 Call for patient input 2012-11-23 Patient input deadline 2012-12-21 Status Active Submission status report Recommendation -
Abatacept
Brand name Orencia Manufacturer Bristol-Myers Squibb Canada Indication Arthritis, Rheumatoid Submission type Resubmission #1 Project Number S0187 Date submission received 2009-12-02 Status Complete Submission status report Date recommendation issued 2010-06-17 Recommendation and reasons Recommendation List in a similar manner -
Abatacept
Brand name Orencia Manufacturer Bristol-Myers Squibb Canada Indication Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid Submission type New Indication Project Number S0145 Date submission received 2008-08-29 Status Complete Submission status report Date recommendation issued 2009-04-22 Recommendation and reasons Recommendation List with criteria/condition -
Abatacept
Brand name Orencia Manufacturer Bristol-Myers Squibb Canada Indication Arthritis, Rheumatoid Submission type Initial Project Number S0084 Date submission received 2006-10-26 Status Complete Submission status report Date recommendation issued 2007-06-27 Recommendation and reasons Recommendation List with criteria/condition -
Acamprosate calcium
Brand name Campral Manufacturer Prempharm Inc. Indication Alcohol Abstinence Submission type Request for Advice Project Number S0143 Date submission received 2008-07-22 Status Complete Submission status report Recommendation -
Acamprosate calcium
Brand name Campral Manufacturer Prempharm Inc. Indication Alcohol Abstinence Submission type Initial Project Number S0108 Date submission received 2007-08-29 Status Complete Submission status report Date recommendation issued 2008-03-27 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation Summary of CEDAC Discussion Summary of CEDAC Discussion Overview of CDR reports Overview of CDR reports -
Adalimumab
Brand name Humira Manufacturer AbbVie Corporation Indication Arthritis, Juvenile Idiopathic Submission type New Indication Project Number SR0308 Date submission received 2013-02-04 Call for patient input 2013-01-04 Patient input deadline 2013-02-22 Status Active Submission status report Recommendation -
Adalimumab
Brand name Humira Manufacturer Abbott Laboratories, Limited Indication Psoriasis Submission type New Indication Project Number S0130 Date submission received 2008-04-15 Status Complete Submission status report Date recommendation issued 2008-10-16 Recommendation and reasons Recommendation List with criteria/condition -
Adalimumab
Brand name Humira Manufacturer Abbott Laboratories, Limited Indication Crohn's disease Submission type Resubmission #3 Project Number S0105 Date submission received 2007-07-12 Status Complete Submission status report Date recommendation issued 2007-12-19 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation Summary of CEDAC Discussion Summary of CEDAC Discussion Overview of CDR reports Overview of CDR reports -
Adalimumab
Brand name Humira Manufacturer Abbott Laboratories, Limited Indication Ankylosing spondylitis (AS) Submission type Resubmission #2 Project Number S0087 Date submission received 2006-11-17 Status Complete Submission status report Date recommendation issued 2007-06-27 Recommendation and reasons Recommendation List with criteria/condition -
Adalimumab
Brand name Humira Manufacturer Abbott Laboratories Limited Indication Arthritis, Psoriatic Submission type Resubmission #1 Project Number S0066 Date submission received 2006-06-21 Status Complete Submission status report Date recommendation issued 2006-11-29 Recommendation and reasons Recommendation List with criteria/condition -
Adalimumab
Brand name Humira Manufacturer Abbott Laboratories Limited Indication Arthritis, Rheumatoid Submission type Initial Project Number S0022 Date submission received 2004-09-24 Status Complete Submission status report Date recommendation issued 2005-02-11 Recommendation and reasons Recommendation List with criteria/condition -
Adefovir dipivoxil
Brand name Hepsera Manufacturer gilead Sciences Canada Inc. Indication Hepatitis B Submission type Request for Advice Project Number S0103 Date submission received 2007-06-29 Status Complete Submission status report Date recommendation issued 2007-10-18 Recommendation and reasons Recommendation List with criteria/condition -
Adefovir dipivoxil
Brand name Hepsera Manufacturer Gilead Sciences Canada Inc. Indication Hepatitis B Submission type Initial Project Number S0060 Date submission received 2006-04-24 Status Complete Submission status report Date recommendation issued 2006-11-29 Recommendation and reasons Recommendation Do not list -
Agalsidase alfa
Brand name Replagal Manufacturer Transkaryotic Therapies Inc. Indication Fabry Disease Submission type Initial Project Number S0006 Date submission received 2004-02-19 Status Complete Submission status report Date recommendation issued 2004-11-24 Recommendation and reasons Recommendation Do not list -
Agalsidase beta
Brand name Fabrazyme Manufacturer Genzyme Canada Indication Fabry Disease Submission type Resubmission #1 Project Number S0028 Date submission received 2004-12-10 Status Complete Submission status report Date recommendation issued 2005-05-18 Recommendation and reasons Recommendation Do not list -
Agalsidase beta
Brand name Fabrazyme Manufacturer Genzyme Canada Indication Fabry Disease Submission type Initial Project Number S0007 Date submission received 2004-02-24 Status Complete Submission status report Date recommendation issued 2004-11-24 Recommendation and reasons Recommendation Do not list -
Alefacept
Brand name Amevive Manufacturer Biogen Idec Canada Inc. Indication Psoriasis, moderate to severe chronic plaque Submission type Resubmission #1 Project Number S0053 Date submission received 2006-02-28 Status Complete Submission status report Date recommendation issued 2006-09-27 Recommendation and reasons Recommendation Do not list -
Alefacept
Brand name Amevive Manufacturer Biogen Idec Canada Inc. Indication Psoriasis, moderate to severe chronic plaque Submission type Initial Project Number S0024 Date submission received 2004-11-16 Status Complete Submission status report Date recommendation issued 2005-05-26 Recommendation and reasons Recommendation Do not list -
Alendronate sodium / cholecalciferol
Brand name Fosavance 70/5600 Manufacturer Merck Frosst Canda Ltd. Indication Osteoporosis Submission type Initial Project Number S0153 Date submission received 2008-12-18 Status Complete Submission status report Date recommendation issued 2009-06-17 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Alendronate sodium / cholecalciferol
Brand name Fosavance Manufacturer Merck Frosst Canda Ltd. Indication Osteoporosis Submission type Initial Project Number S0059 Date submission received 2006-03-27 Status Complete Submission status report Date recommendation issued 2006-09-27 Recommendation and reasons Recommendation Do not list -
Alglucosidase
Brand name Myozyme Manufacturer Genzyme Canada Inc. Indication Pompe’s disease Submission type Initial Project Number S0080 Date submission received 2006-10-10 Status Complete Submission status report Date recommendation issued 2007-06-14 Recommendation and reasons Recommendation List with criteria/condition -
Aliskiren
Brand name Rasilez Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Hypertension Submission type Initial Project Number S0118 Date submission received 2007-11-30 Status Complete Submission status report Date recommendation issued 2008-06-25 Recommendation and reasons Recommendation Do not list -
Alitretinoin
Brand name Toctino Manufacturer Actelion Indication Eczema Submission type Initial Project Number S0232 Date submission received 2011-05-06 Call for patient input 2011-05-09 Patient input deadline 2011-05-30 Status Complete Submission status report Date recommendation issued 2011-10-24 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Almotriptan
Brand name Axert Manufacturer Janssen-Ortho Inc. Indication Migraine Submission type Initial Project Number S0005 Date submission received 2003-12-24 Status Complete Submission status report Date recommendation issued 2004-05-27 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Ambrisentan
Brand name Volibris Manufacturer GlaxoSmithKline Inc. Indication Pulmonary arterial hypertension (WHO class II and III) Submission type Initial Project Number S0142 Date submission received 2008-07-09 Status Complete Submission status report Date recommendation issued 2008-12-17 Recommendation and reasons Recommendation List with criteria/condition -
Amlodipine besylate / atorvastatin calcium
Brand name Caduet Manufacturer Pfizer Canada Inc. Indication Hypertension/ Dyslipidemia Submission type Initial Project Number S0048 Date submission received 2005-12-15 Status Complete Submission status report Date recommendation issued 2006-05-17 Recommendation and reasons Recommendation List with criteria/condition -
Apixaban
Brand name Eliquis Manufacturer Bristol-Myers Squibb Canada and Pfizer Canada Inc. Alliance Indication Thromboembolic events prevention, (atrial fibrillation) Submission type New Indication Project Number SR0288 Date submission received 2012-09-25 Call for patient input 2012-09-07 Patient input deadline 2012-10-15 Status Complete Submission status report Date recommendation issued 2013-03-20 Recommendation and reasons Recommendation List with criteria/condition -
Apixaban
Brand name Eliquis Manufacturer Bristol-Myers Squibb and Pfizer Canada Alliance Indication Thromboembolic events, (venous) prevention Submission type Initial Project Number S0264 Date submission received 2011-12-20 Call for patient input 2011-12-19 Patient input deadline 2012-01-17 Status Complete Submission status report Date recommendation issued 2012-06-14 Recommendation and reasons Recommendation List with criteria/condition -
Aprepitant
Brand name Emend Manufacturer Merck Frosst Canada Ltd. Indication Nausea and Vomiting, Chemotherapy induced Submission type Initial Project Number S0109 Date submission received 2007-08-29 Status Complete Submission status report Date recommendation issued 2008-02-20 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation Summary of CEDAC Discussion Summary of CEDAC Discussion Overview of CDR reports Overview of CDR reports -
Aripiprazole
Brand name Abilify Manufacturer Bristol-Myers Squibb Indication Schizophrenia and Related Psychotic Disorders Submission type Request for Advice Project Number S0226 Date submission received 2011-03-29 Status Complete Submission status report Date recommendation issued 2011-07-18 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Aripiprazole
Brand name Abilify Manufacturer Bristol-Myers Squibb Canada Indication Schizophrenia Submission type Initial Project Number S0183 Date submission received 2009-11-06 Status Complete Submission status report Date recommendation issued 2010-04-27 Recommendation and reasons Recommendation Do not list -
Asenapine
Brand name Saphris Manufacturer Lundbeck Canada Inc. Indication Schizophrenia Submission type Initial Project Number S0262-000 Date submission received 2011-12-12 Call for patient input 2011-12-02 Patient input deadline 2012-01-09 Status Complete Submission status report Date recommendation issued 2012-06-14 Recommendation and reasons Recommendation Do not list -
Asenapine
Brand name Saphris Manufacturer Lundbeck Canada Inc. Indication Bipolar I disorder Submission type Initial Project Number S0262-001 Date submission received 2011-12-12 Call for patient input 2011-12-02 Patient input deadline 2012-01-09 Status Complete Submission status report Date recommendation issued 2012-06-14 Recommendation and reasons Recommendation List with criteria/condition -
Atazanavir
Brand name Reyataz Manufacturer Bristol Myers Squibb Indication HIV infection Submission type Initial Project Number S0002 Date submission received 2003-12-16 Status Complete Submission status report Date recommendation issued 2004-05-27 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Atomoxetine hydrochloride
Brand name Strattera Manufacturer Eli Lilly Canada Inc. Indication Attention deficit hyperactivity disorder Submission type Request for Advice Project Number S0085 Date submission received 2006-09-25 Status Complete Submission status report Recommendation -
Atomoxetine hydrochloride
Brand name Strattera Manufacturer Eli Lilly Canada Inc. Indication Attention deficit hyperactivity disorder Submission type Initial Project Number S0031 Date submission received 2005-01-25 Status Complete Submission status report Date recommendation issued 2005-09-28 Recommendation and reasons Recommendation Do not list -
Azelaic acid
Brand name Finacea Manufacturer Bayer Inc. Indication Rosacea Submission type Initial Project Number S0209 Date submission received 2010-08-31 Call for patient input 2010-08-31 Patient input deadline 2010-09-22 Status Complete Submission status report Date recommendation issued 2011-02-16 Recommendation and reasons Recommendation List Plain language recommendation Plain language recommendation -
Azilsartan medoxomil
Brand name Edarbi Manufacturer Takeda Canada Inc. Indication Hypertension, essential Submission type Initial Project Number SR0317 Date submission received 2013-03-08 Call for patient input 2013-03-08 Patient input deadline 2013-03-29 Status Active Submission status report Recommendation -
Azilsartan medoxomil + chlorthalidone
Brand name Edarbyclor Manufacturer Takeda Canada Inc. Indication Hypertension, essential Submission type Initial Project Number SR0318 Date submission received 2013-03-08 Call for patient input 2013-03-08 Patient input deadline 2013-03-29 Status Active Submission status report Recommendation -
Aztreonam for inhalation solution
Brand name Cayston Manufacturer Gilead Sciences Canada Inc. Indication Cystic fibrosis (CF) with chronic pulmonary pseudomonas aeruginosa infections Submission type Initial Project Number S0220 Date submission received 2010-12-02 Call for patient input 2010-11-26 Patient input deadline 2011-01-31 Status Complete Submission status report Date recommendation issued 2011-07-18 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Belimumab
Brand name Benlysta Manufacturer GlaxoSmithKline Inc. Indication Systemic lupus erythematosus Submission type Initial Project Number S0251 Date submission received 2011-09-19 Call for patient input 2011-08-30 Patient input deadline 2011-10-11 Status Complete Submission status report Date recommendation issued 2012-04-25 Recommendation and reasons Recommendation Do not list -
Boceprevir
Brand name Victrelis Manufacturer Merck Canada Inc. Indication Hepatitis C infection, chronic Submission type Request for Advice Project Number SF0312 Date submission received 2013-02-19 Status Active Submission status report Recommendation -
Boceprevir
Brand name Victrelis Manufacturer Merck Canada Inc. Indication Hepatitis C, chronic Submission type Request for Advice Project Number SF0303 Date submission received 2012-12-21 Status Active Submission status report Recommendation -
Boceprevir
Brand name Victrelis Manufacturer Merck Canada Inc. Indication Hepatitis C, chronic Submission type Pre-NOC Project Number S0231 Date submission received 2011-05-03 Call for patient input 2011-04-25 Patient input deadline 2011-05-26 Status Complete Submission status report Date recommendation issued 2011-10-24 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Brimonidine tartrate / timolol maleate
Brand name Combigan Ophthalmic Solution Manufacturer Allergan Canada Inc. Indication Glaucoma Submission type Initial Project Number S0001 Date submission received 2003-12-15 Status Complete Submission status report Date recommendation issued 2004-05-27 Recommendation and reasons Recommendation List with criteria/condition -
Brinzolamide and timolol maleate suspension
Brand name Azarga Manufacturer Alcon Canada Inc. Indication Glaucoma and ocular hypertension Submission type Initial Project Number S0173 Date submission received 2009-08-28 Status Complete Submission status report Date recommendation issued 2010-02-18 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Buprenorphine transdermal patch
Brand name BuTrans Manufacturer Purdue Pharma Indication Pain, persistent (moderate intensity) Submission type Resubmission #1 Project Number S0233 Date submission received 2011-05-09 Status Complete Submission status report Date recommendation issued 2011-09-28 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Buprenorphine transdermal patch
Brand name BuTrans Manufacturer Purdue Pharma Indication Pain, persistent (moderate intensity) Submission type Initial Project Number S0211 Date submission received 2010-10-15 Call for patient input 2010-10-19 Patient input deadline 2010-11-05 Status Stopped Submission status report Recommendation -
Buprenorphine / naloxone
Brand name Suboxone Manufacturer Schering-Plough Canada Inc Indication Opioid drug dependence (Substitution treatment) Submission type Initial Project Number S0128 Date submission received 2008-03-06 Status Complete Submission status report Date recommendation issued 2008-09-24 Recommendation and reasons Recommendation List with criteria/condition -
Butoconazole nitrate
Brand name Gynazole.1 Manufacturer Ferring Pharmaceuticals Indication Vaginal infection Submission type Initial Project Number S0017 Date submission received 2004-06-30 Status Complete Submission status report Date recommendation issued 2005-01-26 Recommendation and reasons Recommendation Do not list -
Calcitriol
Brand name Silkis Manufacturer Galderma Canada Inc. Indication Psoriasis, mild to moderate plaque Submission type Initial Project Number S0199 Date submission received 2010-03-15 Status Complete Submission status report Date recommendation issued 2010-09-22 Recommendation and reasons Recommendation Do not list -
Canakinumab
Brand name Ilaris Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Cryopyrin-Associated Periodic Syndrome (CAPS) Submission type Initial Project Number S0204 Date submission received 2010-07-07 Call for patient input 2010-06-30 Patient input deadline 2010-07-28 Status Complete Submission status report Date recommendation issued 2011-01-26 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Carbidopa, levodopa and entacapone
Brand name Stalevo Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Parkinsons Disease Submission type Initial Project Number S0131 Date submission received 2008-04-15 Status Complete Submission status report Date recommendation issued 2008-10-16 Recommendation and reasons Recommendation List in a similar manner -
Certolizumab pegol
Brand name Cimzia Manufacturer UCB Pharma Canada Inc. Indication Arthritis, rheumatoid Submission type Initial Project Number S0175 Date submission received 2009-09-03 Status Complete Submission status report Date recommendation issued 2010-05-27 Recommendation and reasons Recommendation Do not list -
Ciclesonide
Brand name Alvesco Manufacturer Altana Pharma Inc. Indication asthma Submission type Initial Project Number S0074 Date submission received 2006-07-24 Status Complete Submission status report Date recommendation issued 2006-12-20 Recommendation and reasons Recommendation List -
Ciclesonide nasal spray
Brand name Omnaris Manufacturer Nycomed Canada Inc. Indication Allergic Rhinitis (seasonal and perennial) Submission type Initial Project Number S0137 Date submission received 2008-05-07 Status Complete Submission status report Date recommendation issued 2008-11-12 Recommendation and reasons Recommendation Do not list -
Cinacalcet hydrochloride
Brand name Sensipar Manufacturer Amgen Canada Inc. Indication Secondary hyper-parathyroidism in chronic kidney disease Submission type Initial Project Number S0018 Date submission received 2004-08-20 Status Complete Submission status report Date recommendation issued 2005-03-23 Recommendation and reasons Recommendation Do not list -
Ciprofloxacin hydrochloride & dexamethasone otic suspension
Brand name Ciprodex Manufacturer Alcon Canada Inc. Indication Otitis media with otorrhea & otitis externa, acute Submission type Request for Advice Project Number S0101 Date submission received 2007-06-15 Status Complete Submission status report Date recommendation issued 2007-10-18 Recommendation and reasons Recommendation List with criteria/condition -
Ciprofloxacin hydrochloride and dexamethasone otic suspension
Brand name Ciprodex Manufacturer Alcon Canada Inc. Indication Otitis media with otorrhea & otitis externa, acute Submission type Initial Project Number S0014 Date submission received 2004-06-11 Status Complete Submission status report Date recommendation issued 2005-01-26 Recommendation and reasons Recommendation Do not list -
Clostridium botulinum neurotoxin type A, free from complexing proteins
Brand name Xeomin Manufacturer Merz Pharmaceuticals GmbH Indication Blepharospasm Submission type Initial Project Number S0168 Date submission received 2009-06-12 Status Complete Submission status report Date recommendation issued 2009-12-16 Recommendation and reasons Recommendation List in a similar manner -
Clostridium botulinum neurotoxin type A, free from complexing proteins
Brand name Xeomin Manufacturer Merz Pharmaceuticals GmbH Indication Cervical Dystonia Submission type Initial Project Number S0192 Date submission received 2009-06-12 Status Complete Submission status report Date recommendation issued 2009-12-16 Recommendation and reasons Recommendation List in a similar manner -
Clostridium botulinum neurotoxin type A, free from complexing proteins
Brand name Xeomin Manufacturer Merz Pharmaceuticals GmbH Indication Spasticity, Post-stroke Submission type Initial Project Number S0193 Date submission received 2009-06-12 Status Complete Submission status report Date recommendation issued 2009-12-16 Recommendation and reasons Recommendation Do not list -
Colesevelam hydrochloride
Brand name Lodalis Manufacturer Valeant Canada LP Indication Hypercholesterolemia Submission type Initial Project Number SR0274 Date submission received 2012-04-27 Call for patient input 2012-04-16 Patient input deadline 2012-05-22 Status Complete Submission status report Date recommendation issued 2012-12-19 Recommendation and reasons Recommendation Do not list at the submitted price -
Collagenase clostridium histolyticum
Brand name Xiaflex Manufacturer Auxilium Pharmaceuticals, Inc. & Actelion Pharmaceuticals Canada Inc. Indication Dupuytren’s contracture with a palpable cord Submission type Initial Project Number SR0287 Date submission received 2012-08-30 Call for patient input 2012-08-20 Patient input deadline 2012-09-24 Status Complete Submission status report Date recommendation issued 2013-03-27 Recommendation and reasons Recommendation List with clinical criteria and/or conditions -
Cyclosporine
Brand name Restasis ophthalmic emulsion Manufacturer Allergan Inc. Indication Dry eye disease, Moderate to moderately severe Submission type Initial Project Number S0222 Date submission received 2010-12-17 Call for patient input 2010-12-02 Patient input deadline 2011-02-07 Status Complete Submission status report Date recommendation issued 2011-07-18 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Dabigatran
Brand name Pradaxa Manufacturer Boehringer Ingelheim (Canada) Ltd Indication Atrial fibrillation prevention of stroke and systemic embolism Submission type Request for Advice Project Number SF0320-000 Date submission received 2013-03-18 Status Active Submission status report Recommendation -
Dabigatran etexilate
Brand name Pradax Manufacturer Boehringer Ingelheim Indication Atrial fibrillation prevention of stroke and systemic embolism Submission type New Indication Project Number S0214 Date submission received 2010-10-28 Call for patient input 2010-10-29 Patient input deadline 2010-11-18 Status Complete Submission status report Date recommendation issued 2011-06-22 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Dabigatran etexilate
Brand name Pradax Manufacturer Boehringer-Ingelheim (Canada) Ltd. Indication Atrial fibrillation prevention of stroke and systemic embolism Submission type Pre-NOC - New Indication Project Number S0202 Date submission received 2010-05-31 Call for patient input 2010-06-04 Patient input deadline 2010-06-25 Status Rejected Submission status report Recommendation -
Dabigatran etexilate
Brand name Pradax Manufacturer Boehringer Ingelheim (Canada) Ltd. Indication Thromboembolism (venous), prevention Submission type Initial Project Number S0140 Date submission received 2008-07-08 Status Complete Submission status report Date recommendation issued 2009-01-28 Recommendation and reasons Recommendation Do not list -
Daptomycin
Brand name Cubicin Manufacturer Cubist Pharmaceuticals Inc. Indication Skin and skin structure infections & bacteremia Submission type Initial Project Number S0127 Date submission received 2008-03-06 Status Complete Submission status report Date recommendation issued 2008-09-24 Recommendation and reasons Recommendation Do not list -
Darifenacin hydrobromide
Brand name Enablex Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Bladder, overactive Submission type Resubmission #1 Project Number S0147 Date submission received 2008-10-01 Status Complete Submission status report Date recommendation issued 2009-04-16 Recommendation and reasons Recommendation List with criteria/condition -
Darifenacin hydrobromide
Brand name Enablex Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Bladder, overactive Submission type Initial Project Number S0061 Date submission received 2006-04-26 Status Complete Submission status report Date recommendation issued 2006-10-19 Recommendation and reasons Recommendation Do not list -
Darunavir
Brand name Prezista Manufacturer Janssen-Ortho Inc. Indication HIV infection (Pediatric) Submission type New Indication Project Number S0194 Date submission received 2009-12-22 Status Complete Submission status report Date recommendation issued 2010-06-17 Recommendation and reasons Recommendation List with criteria/condition -
Darunavir
Brand name Prezista Manufacturer Janssen-Ortho Inc. Indication HIV (treatment naive) Submission type New Indication Project Number S0163 Date submission received 2009-03-27 Status Complete Submission status report Date recommendation issued 2009-10-14 Recommendation and reasons Recommendation List with criteria/condition -
Darunavir
Brand name Prezista Manufacturer Janssen-Ortho Inc. Indication HIV infection Submission type Initial Project Number S0072 Date submission received 2006-08-29 Status Complete Submission status report Date recommendation issued 2007-02-14 Recommendation and reasons Recommendation List with criteria/condition -
Deferasirox
Brand name Exjade Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Iron overload Submission type Initial Project Number S0081 Date submission received 2006-10-26 Status Complete Submission status report Date recommendation issued 2007-04-19 Recommendation and reasons Recommendation List with criteria/condition -
Delta-9-tetrahydrocannabinol / cannabidiol
Brand name Sativex Manufacturer GW Pharma Ltd. Indication Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids) Submission type Resubmission #1 Project Number S0106 Date submission received 2007-08-07 Status Complete Submission status report Date recommendation issued 2008-02-20 Recommendation and reasons Recommendation Do not list -
Delta-9-tetrahydrocannabinol / cannabidiol
Brand name Sativex Manufacturer GW Pharma Ltd. Indication Pain, Neuropathic (adjunctive) in MS. Submission type Initial Project Number S0092 Date submission received 2007-02-27 Status Complete Submission status report Date recommendation issued 2007-09-26 Recommendation and reasons Recommendation Do not list -
Denosumab
Brand name XGEVA Manufacturer Amgen Canada Inc. Indication Prevention of skeletal-related events due to bone metastases from solid tumours Submission type New Indication Project Number S0235 Date submission received 2011-06-06 Call for patient input 2011-05-27 Patient input deadline 2011-06-24 Status Complete Submission status report Date recommendation issued 2011-11-16 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Denosumab
Brand name Prolia Manufacturer Amgen Canada Inc. Indication Osteoporosis, postmenopausal women Submission type Initial Project Number S0208 Date submission received 2010-08-26 Call for patient input 2010-08-13 Patient input deadline 2010-09-17 Status Complete Submission status report Date recommendation issued 2011-03-30 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Desvenlafaxine succinate
Brand name Pristiq Manufacturer Wyeth Canada Indication Depressive, Major Disorder (MDD) Submission type Initial Project Number S0159 Date submission received 2009-03-05 Status Complete Submission status report Date recommendation issued 2009-09-23 Recommendation and reasons Recommendation Do not list -
Dexamethasone intravitreal implant
Brand name Ozurdex Manufacturer Allergan Indication Macular edema following central retinal vein occlusion Submission type Initial Project Number S0247 Date submission received 2011-09-01 Call for patient input 2011-08-19 Patient input deadline 2011-09-23 Status Complete Submission status report Date recommendation issued 2012-04-25 Recommendation and reasons Recommendation Do not list -
Dienogest
Brand name Visanne Manufacturer Bayer Inc. Indication Pain (pelvic) associated with endometriosis Submission type Initial Project Number S0255 Date submission received 2011-10-18 Call for patient input 2011-10-18 Patient input deadline 2011-11-08 Status Complete Submission status report Date recommendation issued 2012-04-19 Recommendation and reasons Recommendation List with criteria/condition -
Dimethyl fumarate
Brand name Tecfidera Manufacturer Biogen Idec Canada Inc. Indication Multiple Sclerosis, relapsing Submission type Pre-NOC Project Number SR0309 Date submission received 2013-02-04 Call for patient input 2013-01-18 Patient input deadline 2013-03-04 Status Active Submission status report Recommendation -
Doxycycline monohydrate
Brand name Apprilon Manufacturer Galderma Canada Inc. Indication Rosacea treatment Submission type Initial Project Number SR0279 Date submission received 2012-04-27 Call for patient input 2012-04-19 Patient input deadline 2012-05-22 Status Complete Submission status report Date recommendation issued 2013-03-27 Recommendation and reasons Recommendation Do not list -
Dronedarone hydrochloride
Brand name Multaq Manufacturer Sanofi-Aventis Canada Inc. Indication Atrial fibrillation Submission type Initial Project Number S0177 Date submission received 2009-09-18 Status Complete Submission status report Date recommendation issued 2010-05-27 Recommendation and reasons Recommendation Do not list -
Drospirenone / ethinyl estradiol
Brand name Yasmin Manufacturer Berlex Canada Inc. Indication Contraceptive, oral Submission type Initial Project Number S0029 Date submission received 2005-01-20 Status Complete Submission status report Date recommendation issued 2005-06-16 Recommendation and reasons Recommendation List -
Duloxetine hydrochloride
Brand name Cymbalta Manufacturer Eli Lilly Canada Inc. Indication Pain, Neuropathic, Diabetic Submission type Initial Project Number S0126 Date submission received 2008-02-08 Status Complete Submission status report Date recommendation issued 2008-08-14 Recommendation and reasons Recommendation List with criteria/condition -
Duloxetine hydrochloride
Brand name Cymbalta Manufacturer Eli Lilly Canada Inc. Indication Depressive, Major Disorder (MDD) Submission type Initial Project Number S0125 Date submission received 2008-02-08 Status Complete Submission status report Date recommendation issued 2008-08-14 Recommendation and reasons Recommendation Do not list -
Dutasteride
Brand name Avodart Manufacturer GlaxoSmithKline Inc. Indication Prostatic hyperplasia, benign Submission type Initial Project Number S0019 Date submission received 2004-08-24 Status Complete Submission status report Date recommendation issued 2005-01-20 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Eculizumab
Brand name Soliris Manufacturer Alexion Pharma Canada Indication Hemolytic Uremic Syndrome, Atypical Submission type Pre-NOC Project Number SR0304 Date submission received 2013-01-07 Call for patient input 2012-12-06 Patient input deadline 2013-01-28 Status Active Submission status report Recommendation -
Eculizumab
Brand name Soliris Manufacturer Alexion Pharmaceuticals Inc. Indication Paroxysmal nocturnal hemoglobinuria (PNH) Submission type Initial Project Number S0176 Date submission received 2009-09-18 Status Complete Submission status report Date recommendation issued 2010-02-18 Recommendation and reasons Recommendation Do not list -
Efalizumab
Brand name Raptiva Manufacturer Serono Canada Inc. Indication Psoriasis, moderate to severe chronic plaque Submission type Request for Advice Project Number S0102 Date submission received 2007-06-19 Status Complete Submission status report Recommendation -
Efalizumab
Brand name Raptiva Manufacturer Serono Canada Inc. Indication Psoriasis, moderate to severe chronic plaque Submission type Initial Project Number S0043 Date submission received 2005-10-25 Status Complete Submission status report Date recommendation issued 2006-08-24 Recommendation and reasons Recommendation List with criteria/condition -
Efavirenz, emtricitabine, tenofovir disoproxil fumarate
Brand name Atripla Manufacturer Bristol-Myers Squibb and Gilead Sciences Indication HIV Submission type Initial Project Number S0111 Date submission received 2007-10-30 Status Complete Submission status report Date recommendation issued 2008-04-17 Recommendation and reasons Recommendation List with criteria/condition -
Eletriptan hydrobromide
Brand name Relpax Manufacturer Pfizer Canada Inc. Indication Migraine Submission type Initial Project Number S0021 Date submission received 2004-09-21 Status Complete Submission status report Date recommendation issued 2005-03-23 Recommendation and reasons Recommendation Do not list -
Eltrombopag olamine
Brand name Revolade Manufacturer GlaxoSmithKline Indication Thrombocytopenic purpura chronic immune (idiopathic) Submission type Initial Project Number S0230 Date submission received 2011-04-26 Call for patient input 2011-04-26 Patient input deadline 2011-05-17 Status Complete Submission status report Date recommendation issued 2011-10-24 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate
Brand name Stribild Manufacturer Gilead Sciences Canada Inc. Indication HIV-1 infection Submission type Initial Project Number SR0301 Date submission received 2012-11-30 Call for patient input 2012-11-19 Patient input deadline 2012-12-21 Status Complete Submission status report Date recommendation issued 2013-05-15 Recommendation and reasons Recommendation List with clinical criteria and/or conditions -
Emtricitabine / rilpivirine / tenofovir disoproxil fumarate
Brand name COMPLERA Manufacturer Gilead Science Canada Ltd. Indication HIV-1 infection in antiretroviral treatment- naïve adults Submission type Initial Project Number S0256 Date submission received 2011-10-19 Call for patient input 2011-10-11 Patient input deadline 2011-11-09 Status Complete Submission status report Date recommendation issued 2012-04-19 Recommendation and reasons Recommendation List -
Emtricitabine / tenofovir disoproxil fumarate
Brand name Truvada Manufacturer Gilead Sciences Canada Inc. Indication HIV infection Submission type Request for Advice Project Number S0138 Date submission received 2008-07-07 Status Complete Submission status report Date recommendation issued 2008-12-17 Recommendation and reasons Recommendation List with criteria/condition -
Emtricitabine / tenofovir disoproxil fumarate
Updated recommendation issued 2008-12-17 Recommendation and reasons Brand name Truvada Manufacturer Gilead Sciences Canada Inc. Indication HIV infection Submission type Initial Project Number S0063 Date submission received 2006-05-29 Status Complete Submission status report Date recommendation issued 2006-10-25 Recommendation and reasons Recommendation List with criteria/condition -
Entecavir
Brand name Baraclude Manufacturer Bristol-Myers Squibb Canada Indication Hepatitis B (chronic) Submission type Initial Project Number S0089 Date submission received 2006-12-12 Status Complete Submission status report Date recommendation issued 2007-11-28 Recommendation and reasons Recommendation List with criteria/condition -
Eplerenone
Brand name Inspra Manufacturer Pfizer Canada Inc. Indication Post myocardial infarction Submission type Initial Project Number S0165 Date submission received 2009-05-06 Status Complete Submission status report Date recommendation issued 2009-11-25 Recommendation and reasons Recommendation Do not list -
Eprosartan mesylate / hydrochlorothiazide
Brand name Teveten Plus Manufacturer Solvay Pharma Inc. Indication Hypertension, Essential Submission type Initial Project Number S0016 Date submission received 2004-07-08 Status Complete Submission status report Date recommendation issued 2004-12-15 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Erlotinib
Brand name Tarceva Manufacturer Hoffmann-La Roche Limited Indication Cancer, Lung , non-small cell Submission type Initial Project Number S0037 Date submission received 2005-07-19 Status Complete Submission status report Date recommendation issued 2005-12-07 Recommendation and reasons Recommendation List with criteria/condition -
Escitalopram oxalate
Brand name Cipralex Manufacturer Lundbeck Canada Inc. Indication Depression, Major Depressive Disorder (MDD) Submission type Resubmission #1 Project Number S0064 Date submission received 2006-06-08 Status Complete Submission status report Date recommendation issued 2007-01-24 Recommendation and reasons Recommendation Do not list -
Escitalopram oxalate
Brand name Cipralex Manufacturer Lundbeck Canada Inc. Indication Depression, Major Depressive Disorder (MDD) Submission type Initial Project Number S0039 Date submission received 2005-08-03 Status Withdrawn Submission status report Recommendation -
Etonogestrel / ethinyl estradiol
Brand name NuvaRing Manufacturer Organon Canada Ltd. Indication Contraceptive, ring Submission type Initial Project Number S0062 Date submission received 2006-05-05 Status Complete Submission status report Date recommendation issued 2006-11-29 Recommendation and reasons Recommendation List with criteria/condition -
Etravirine
Brand name Intelence Manufacturer Janssen-Ortho Inc. Indication HIV Submission type Initial Project Number S0129 Date submission received 2008-04-02 Status Complete Submission status report Date recommendation issued 2008-08-14 Recommendation and reasons Recommendation List with criteria/condition -
Everolimus
Brand name Afinitor Manufacturer Novartis Pharmaceuticals Canada Inc. Indication renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Submission type Initial Project Number SR0315-000 Date submission received 2013-03-08 (Tentative) Call for patient input 2013-02-14 Patient input deadline 2013-04-01 Status Active Submission status report Recommendation -
Exenatide
Brand name Byetta Manufacturer Eli Lilly Canada Indication Diabetes mellitus, Type 2 Submission type Initial Project Number S0246 Date submission received 2011-08-23 Call for patient input 2011-08-09 Patient input deadline 2011-09-14 Status Complete Submission status report Date recommendation issued 2012-07-19 Recommendation and reasons Recommendation Do not list -
Fampridine
Brand name Fampyra Manufacturer Biogen Idec Canada Inc. Indication Multiple Sclerosis, improve walking disability Submission type Initial Project Number SR0275 Date submission received 2012-04-16 Call for patient input 2012-04-10 Patient input deadline 2012-05-04 Status Complete Submission status report Date recommendation issued 2012-11-28 Recommendation and reasons Recommendation Do not list -
Febuxostat
Brand name Uloric Manufacturer Takeda Canada Inc. Indication Gout Submission type Initial Project Number S0213 Date submission received 2010-10-27 Call for patient input 2010-09-30 Patient input deadline 2010-11-17 Status Complete Submission status report Date recommendation issued 2011-04-25 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Fentanyl Citrate
Brand name Onsolis Manufacturer Meda Valeant Pharma Canada Inc. Indication Pain (breakthrough), cancer (adults) Submission type Resubmission #1 Project Number S0248 Date submission received 2011-08-22 Status Complete Submission status report Date recommendation issued 2012-02-15 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Fentanyl citrate
Brand name Abstral Manufacturer Paladin Labs Inc. Indication Pain, Cancer (breakthrough) Submission type Initial Project Number S0240 Date submission received 2011-06-30 Call for patient input 2011-06-21 Patient input deadline 2011-07-25 Status Complete Submission status report Date recommendation issued 2011-12-16 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Fentanyl Citrate
Brand name Onsolis Manufacturer Meda Valeant Pharma Canada Inc. Indication Pain (breakthrough), cancer (adults) Submission type Initial Project Number S0229 Date submission received 2011-05-10 Call for patient input 2011-03-04 Patient input deadline 2011-06-01 Status Withdrawn Submission status report Recommendation -
Fesoterodine fumarate
Brand name Toviaz Manufacturer Pfizer Canada Inc. Indication Bladder, overactive Submission type Initial Project Number SR0277 Date submission received 2012-04-27 Call for patient input 2012-04-27 Patient input deadline 2012-05-18 Status Complete Submission status report Date recommendation issued 2012-10-18 Recommendation and reasons Recommendation List in a similar manner -
Fidaxomicin
Brand name Dificid Manufacturer Optimer Pharmaceuticals Canada, Inc. Indication Clostridium difficile infection Submission type Initial Project Number SR0285 Date submission received 2012-07-11 Call for patient input 2012-06-27 Patient input deadline 2012-08-01 Status Complete Submission status report Date recommendation issued 2012-12-19 Recommendation and reasons Recommendation Do not list at the submitted price -
Fingolimod
Brand name Gilenya Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Multiple Sclerosis Submission type Initial Project Number S0228 Date submission received 2011-05-10 Call for patient input 2011-03-11 Patient input deadline 2011-05-09 Status Complete Submission status report Date recommendation issued 2011-11-16 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Fosamprenavir calcium
Brand name Telzir Manufacturer GlaxoSmithKline Inc. Indication HIV infection Submission type Initial Project Number S0030 Date submission received 2005-01-24 Status Complete Submission status report Date recommendation issued 2005-06-16 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Gefitinib
Brand name Iressa Manufacturer AstraZeneca Indication Cancer, Lung , non-small cell Submission type Initial Project Number S0003 Date submission received 2003-12-22 Status Complete Submission status report Date recommendation issued 2004-06-23 Recommendation and reasons Recommendation Do not list -
Glatiramer acetate
Brand name Copaxone Manufacturer Teva Pharmaceutical Industries Ltd. Indication Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis Submission type New Indication Project Number S0164 Date submission received 2009-04-29 Status Complete Submission status report Date recommendation issued 2009-11-25 Recommendation and reasons Recommendation Do not list -
Glycopyrronium bromide
Brand name Seebri Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment Submission type Initial Project Number SR0300 Date submission received 2012-11-30 Call for patient input 2012-11-27 Patient input deadline 2012-12-21 Status Complete Submission status report Date recommendation issued 2013-05-15 Recommendation and reasons Recommendation List with clinical criteria and/or conditions -
Golimumab
Brand name Simponi Manufacturer Centocor Inc. Indication Arthritis, Rheumatoid Submission type Initial Project Number S0174 Date submission received 2009-09-03 Status Complete Submission status report Date recommendation issued 2010-03-17 Recommendation and reasons Recommendation List in a similar manner -
Golimumab
Brand name Simponi Manufacturer Centocor Inc. Indication Arthritis, psoriatic Submission type Initial Project Number S0195 Date submission received 2009-09-03 Status Complete Submission status report Date recommendation issued 2010-03-17 Recommendation and reasons Recommendation List in a similar manner -
Golimumab
Brand name Simponi Manufacturer Centocor Inc. Indication Ankylosing spondylitis Submission type Initial Project Number S0196 Date submission received 2009-09-03 Status Complete Submission status report Date recommendation issued 2010-03-17 Recommendation and reasons Recommendation List in a similar manner -
Grass Pollen Allergen Extract
Brand name Oralair Manufacturer Paladin Labs Inc. Indication Allergic rhinitis (grass pollen) Submission type Initial Project Number SR0290 Date submission received 2012-09-07 Call for patient input 2012-09-07 Patient input deadline 2012-10-15 Status Complete Submission status report Date recommendation issued 2013-03-20 Recommendation and reasons Recommendation List with clinical criteria and/or conditions -
Histrelin acetate
Brand name Vantas Manufacturer Paladin Labs Inc. Indication Cancer, prostate Submission type Initial Project Number S0078 Date submission received 2006-09-20 Status Complete Submission status report Date recommendation issued 2007-04-26 Recommendation and reasons Recommendation Do not list -
Hydromorphone hydrochloride
Brand name Jurnista Manufacturer Janssen-Ortho Inc. Indication Pain, Chronic (moderate to severe) Submission type Initial Project Number S0190 Date submission received 2009-12-04 Status Complete Submission status report Date recommendation issued 2010-05-19 Recommendation and reasons Recommendation Do not list -
Idursulfase
Brand name Elaprase Manufacturer Shire Human Genetic Therapies, Inc. Indication Mucopolysarccharidosis II (MPS II), Hunter Syndrome Submission type Initial Project Number S0104 Date submission received 2007-07-13 Status Complete Submission status report Date recommendation issued 2007-12-19 Recommendation and reasons Recommendation Do not list -
Indacaterol
Brand name Onbrez Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment Submission type Initial Project Number SR0273 Date submission received 2012-02-29 Call for patient input 2012-02-15 Patient input deadline 2012-03-20 Status Complete Submission status report Date recommendation issued 2012-08-16 Recommendation and reasons Recommendation List in a similar manner -
Infliximab
Brand name Remicade Manufacturer Centocor Inc. Indication Ulcerative Colitis Submission type Initial Project Number S0146 Date submission received 2008-09-29 Status Complete Submission status report Date recommendation issued 2009-04-22 Recommendation and reasons Recommendation Do not list -
Ingenol mebutate
Brand name Picato Manufacturer LEO Pharma Inc. Indication Keratosis, actinic Submission type Initial Project Number SR0330 Date submission received 2013-05-09 (Tentative) Call for patient input 2013-05-08 Patient input deadline 2013-06-07 Patient Input Status Active Recommendation -
Insulin aspart / insulin aspart protamine
Brand name NovoMix 30 Manufacturer Novo Nordisk Canada Inc. Indication Diabetes mellitus Submission type Initial Project Number S0041 Date submission received 2005-10-13 Status Complete Submission status report Date recommendation issued 2006-04-26 Recommendation and reasons Recommendation Do not list -
Insulin detemir
Brand name Levemir Manufacturer Novo Nordisk Canada Inc. Indication Diabetes mellitus Submission type Resubmission #2 Project Number S0160 Date submission received 2009-03-10 Status Complete Submission status report Date recommendation issued 2009-08-19 Recommendation and reasons Recommendation Do not list -
Insulin detemir
Brand name Levemir Manufacturer Novo Nordisk Canada Inc. Indication Diabetes mellitus Type1, Pediatrics Submission type New Indication Project Number S0172 Date submission received 2009-03-10 Status Complete Submission status report Date recommendation issued 2009-08-19 Recommendation and reasons Recommendation Do not list -
Insulin detemir
Brand name Levemir Manufacturer Novo Nordisk Canada Inc. Indication Diabetes mellitus Submission type Resubmission #1 Project Number S0158 Date submission received 2009-02-02 Status Withdrawn Submission status report Recommendation -
Insulin detemir
Brand name Levemir Manufacturer Novo Nordisk Canada Inc. Indication Diabetes mellitus Submission type Initial Project Number S0049 Date submission received 2005-12-19 Status Complete Submission status report Date recommendation issued 2006-08-02 Recommendation and reasons Recommendation Do not list -
Insulin glargine (rDNA origin)
Brand name Lantus Manufacturer Sanofi-Aventis Canada Inc. Indication Diabetes mellitus, Type 1 & 2 Submission type Request for Advice Project Number S0166 Date submission received 2009-06-09 Status Complete Submission status report Recommendation -
Insulin glargine (rDNA origin)
Brand name Lantus Manufacturer Sanofi-Aventis Canada Inc. Indication Diabetes mellitus, Type 1 & 2 Submission type Resubmission #1 Project Number S0058 Date submission received 2006-03-27 Status Complete Submission status report Date recommendation issued 2006-10-25 Recommendation and reasons Recommendation Do not list -
Insulin glargine (rDNA origin)
Brand name Lantus Manufacturer Aventis Pharma Inc. Indication Diabetes mellitus, Type 1 & 2 Submission type Initial Project Number S0033 Date submission received 2005-02-11 Status Complete Submission status report Date recommendation issued 2005-09-28 Recommendation and reasons Recommendation Do not list -
Insulin glulisine
Brand name Apidra Manufacturer Sanofi-Aventis Canada Inc. Indication Diabetes, Mellitus (Type 1 & 2) Submission type Initial Project Number S0144 Date submission received 2008-08-29 Status Complete Submission status report Date recommendation issued 2009-02-19 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Interferon beta-1a
Brand name Rebif Manufacturer EMD Serono Indication Clinically Isolated Syndrome Submission type Initial Project Number SR0298 Date submission received 2012-12-14 (Tentative) Call for patient input 2012-11-22 Patient input deadline 2013-01-15 Status Pending Submission status report Recommendation -
Ivacaftor
Brand name Kalydeco Manufacturer Vertex Pharmaceuticals Inc. Indication Cystic Fibrosis patients (G551D mutation) Submission type Pre-NOC Project Number SR0291 Date submission received 2012-09-21 Call for patient input 2012-09-21 Patient input deadline 2012-10-22 Status Complete Submission status report Date recommendation issued 2013-03-22 Recommendation and reasons Recommendation List with clinical criteria and/or conditions -
Lacosamide
Brand name Vimpat Manufacturer UCB Canada Inc. Indication Epilepsy, partial onset seizures (POS) Submission type Initial Project Number S0212 Date submission received 2010-10-25 Call for patient input 2010-10-25 Patient input deadline 2010-11-15 Status Complete Submission status report Date recommendation issued 2011-04-25 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Lanreotide acetate
Brand name Somatuline Autogel Manufacturer Ipsen Limited Indication Acromegaly Submission type Initial Project Number S0091 Date submission received 2007-02-20 Status Complete Submission status report Date recommendation issued 2007-07-19 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Lanthanum carbonate hydrate
Brand name Fosrenol Manufacturer Shire BioChem Inc. Indication Hyperphosphatemia, end-stage renal disease Submission type Initial Project Number S0100 Date submission received 2007-06-28 Status Complete Submission status report Date recommendation issued 2008-01-30 Recommendation and reasons Recommendation Do not list -
Laronidase
Brand name Aldurazyme Manufacturer Genzyme Canada Indication Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie Submission type Initial Project Number S0032 Date submission received 2005-02-03 Status Complete Submission status report Date recommendation issued 2005-07-14 Recommendation and reasons Recommendation Do not list -
Levodopa / carbidopa
Brand name Duodopa Manufacturer Solvay Pharma Inc. Indication Parkinson's disease Submission type Initial Project Number S0154 Date submission received 2008-12-19 Status Complete Submission status report Date recommendation issued 2009-07-22 Recommendation and reasons Recommendation Do not list -
Linagliptin
Brand name Trajenta Manufacturer Boehringer Ingelheim Canada Indication Diabetes mellitus, Type 2 Submission type Initial Project Number S0244 Date submission received 2011-08-23 Call for patient input 2011-08-09 Patient input deadline 2011-09-14 Status Complete Submission status report Date recommendation issued 2012-02-15 Recommendation and reasons Recommendation List with criteria/condition -
Linagliptin-metformin
Brand name Jentadueto Manufacturer Boehringer Ingelheim (Canada) Ltd. Indication Diabetes mellitus (Type 2) Submission type Initial Project Number SR0306 Date submission received 2013-03-08 Call for patient input 2013-01-10 Patient input deadline 2013-03-01 Status Active Submission status report Recommendation -
Liraglutide
Brand name Victoza Manufacturer Novo Nordisk Canada Inc. Indication Diabetes mellitus, Type 2 Submission type Initial Project Number S0217 Date submission received 2010-11-29 Call for patient input 2010-10-12 Patient input deadline 2011-01-10 Status Complete Submission status report Date recommendation issued 2011-09-28 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Lisdexamfetamine dimesylate
Brand name Vyvanse Manufacturer Shire Canada Inc. Indication Attention deficit hyperactivity disorder Submission type Initial Project Number S0171 Date submission received 2009-07-10 Status Complete Submission status report Date recommendation issued 2009-12-18 Recommendation and reasons Recommendation Do not list -
Loteprednol etabonate
Brand name Lotemax Manufacturer Bausch & Lomb Indication Post-operative inflammation following cataract surgery Submission type Initial Project Number S0186 Date submission received 2009-12-02 Status Complete Submission status report Date recommendation issued 2010-05-19 Recommendation and reasons Recommendation Do not list -
Lumiracoxib
Brand name Prexige Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Osteoarthritis (Knee) Submission type Initial Project Number S0090 Date submission received 2006-12-15 Status Complete Submission status report Date recommendation issued 2007-07-25 Recommendation and reasons Recommendation Do not list -
Lurasidone
Brand name Latuda Manufacturer Sunovion Pharmaceuticals Inc. Indication Schizophrenia Submission type Resubmission #1 Project Number SR0331 Date submission received 2013-05-09 Call for patient input 2013-05-09 Patient input deadline 2013-05-31 Patient Input Status Active Recommendation -
Lurasidone
Brand name Latuda Manufacturer Sunovion Pharmaceuticals Inc. Indication schizophrenia Submission type Initial Project Number SR0284 Date submission received 2012-07-03 Call for patient input 2012-06-20 Patient input deadline 2012-07-24 Status Complete Submission status report Date recommendation issued 2013-01-23 Recommendation and reasons Recommendation Do not list -
Maraviroc
Brand name Celsentri Manufacturer GlaxoSmithKline Indication HIV-1, treatment naïve (adult) Submission type New Indication Project Number S0221 Date submission received 2010-12-08 Call for patient input 2010-12-09 Patient input deadline 2011-01-31 Status Complete Submission status report Date recommendation issued 2011-07-18 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Maraviroc
Brand name Celsentri Manufacturer Pfizer Canada Inc. Indication HIV Submission type Resubmission #1 Project Number S0136 Date submission received 2008-05-07 Status Complete Submission status report Date recommendation issued 2008-11-12 Recommendation and reasons Recommendation List with criteria/condition -
Maraviroc
Brand name Celsentri Manufacturer Pfizer Canada Inc. Indication HIV Submission type Initial Project Number S0113 Date submission received 2007-11-02 Status Withdrawn Submission status report Recommendation -
Memantine hydrochloride
Brand name Ebixa Manufacturer Lundbeck Canada Inc. Indication Dementia (Alzheimer type), moderate to severe Submission type Initial Project Number S0025 Date submission received 2004-12-21 Status Complete Submission status report Date recommendation issued 2005-11-23 Recommendation and reasons Recommendation Do not list -
Methylnaltrexone bromide
Brand name Relistor Manufacturer Wyeth Canada Indication Constipation, Opioid-induced Submission type Initial Project Number S0135 Date submission received 2008-05-07 Status Complete Submission status report Date recommendation issued 2009-01-28 Recommendation and reasons Recommendation Do not list -
Miglustat
Brand name Zavesca Manufacturer Actelion Pharmaceuticals Canada Inc. Indication Gaucher disease Submission type Initial Project Number S0012 Date submission received 2004-05-13 Status Complete Submission status report Date recommendation issued 2004-11-24 Recommendation and reasons Recommendation Do not list -
Mirabegron
Brand name Myrbetriq Manufacturer Astellas Pharma Canada, Inc. Indication Bladder, Overactive Submission type Initial Project Number SR0319 Date submission received 2013-03-08 Call for patient input 2013-03-08 Patient input deadline 2013-03-29 Status Active Submission status report Recommendation -
Mixed amphetamine salts
Brand name Adderall XR Manufacturer Shire Canada Inc. Indication Attention deficit hyperactivity disorder, Adult Submission type New Indication Project Number S0116 Date submission received 2007-11-29 Status Complete Submission status report Date recommendation issued 2008-06-25 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation Summary of CEDAC Discussion Summary of CEDAC Discussion Overview of CDR reports Overview of CDR reports -
Mixed amphetamine salts
Brand name Adderall XR Manufacturer Shire BioChem Inc. Indication Attention deficit hyperactivity disorder Submission type Resubmission #1 Project Number S0027 Date submission received 2004-12-15 Status Withdrawn Submission status report Recommendation -
Mixed amphetamine salts
Brand name Adderall XR Manufacturer Shire BioChem Inc. Indication Attention deficit hyperactivity disorder Submission type Initial Project Number S0010 Date submission received 2004-04-13 Status Complete Submission status report Date recommendation issued 2004-11-24 Recommendation and reasons Recommendation Do not list -
Mometasone furoate
Brand name ASMANEX Manufacturer Merck Canada Inc. Indication Asthma, (Bronchial) Prophylactic management of steroid responsive Submission type Initial Project Number SR0258 Date submission received 2011-11-10 Call for patient input 2011-11-17 Patient input deadline 2011-11-21 Status Complete Submission status report Date recommendation issued 2012-05-16 Recommendation and reasons Recommendation List -
Mometasone furoate and formoterol
Brand name Zenhale (inhalation aerosol) Manufacturer Merck Canada Indication Asthma maintenance (adults, children 12 or older) Submission type Initial Project Number S0225 Date submission received 2011-02-16 Call for patient input 2011-01-31 Patient input deadline 2011-03-10 Status Complete Submission status report Date recommendation issued 2011-09-28 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Mometasone / formoterol
Brand name Zenhale Manufacturer Merck Canada Inc. Indication Asthma maintenance (adults, children 12 or older) Submission type Request for Advice Project Number S0281 Date submission received 2012-06-06 Status Complete Submission status report Date recommendation issued 2012-12-19 Recommendation and reasons Recommendation List with criteria/condition -
Mycophenolate sodium
Brand name Myfortic Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Organ rejection in allogeneic renal transplants, Prophylaxis Submission type Initial Project Number S0034 Date submission received 2005-03-03 Status Complete Submission status report Date recommendation issued 2005-07-08 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Natalizumab
Brand name Tysabri Manufacturer Biogen Idec Canada Inc. Indication Multiple Sclerosis, relapsing-remitting Submission type Resubmission #1 Project Number S0133 Date submission received 2008-05-06 Status Complete Submission status report Date recommendation issued 2009-02-25 Recommendation and reasons Recommendation List with criteria/condition -
Natalizumab
Brand name Tysabri Manufacturer Biogen Idec Canada Inc. Indication Multiple Sclerosis, relapsing-remitting Submission type Initial Project Number S0082 Date submission received 2006-10-26 Status Complete Submission status report Date recommendation issued 2007-04-26 Recommendation and reasons Recommendation Do not list -
Nebivolol
Brand name Bystolic Manufacturer Forest Laboratories Canada Inc. Indication Hypertension, essential Submission type Initial Project Number SR0307 Date submission received 2013-02-04 Call for patient input 2013-01-16 Patient input deadline 2013-03-04 Status Active Submission status report Recommendation -
Niacin / lovastatin
Brand name Advicor Manufacturer Oryx Pharmaceuticals Inc. Indication Hypercholesterolemia and mixed dyslipidemia Submission type Initial Project Number S0042 Date submission received 2005-10-18 Status Complete Submission status report Date recommendation issued 2006-04-26 Recommendation and reasons Recommendation List -
Norgelestromin / ethinyl estradiol
Brand name Evra Manufacturer Janssen-Ortho Inc. Indication Contraceptive, patch Submission type Initial Project Number S0004 Date submission received 2003-12-19 Status Complete Submission status report Date recommendation issued 2004-06-23 Recommendation and reasons Recommendation Do not list -
Olmesartan medoxomil
Brand name Olmetec Manufacturer Schering-Plough Canada Inc. Indication Hypertension Submission type Initial Project Number S0150 Date submission received 2008-11-28 Status Complete Submission status report Date recommendation issued 2009-05-27 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Olmesartan medoxomil + hydrochlorothiazide
Brand name Olmetec Plus Manufacturer Schering-Plough Canada Inc. Indication Hypertension Submission type Initial Project Number S0151 Date submission received 2008-11-28 Status Complete Submission status report Date recommendation issued 2009-05-27 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Omalizumab
Brand name Xolair Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Asthma, severe persistent Submission type Resubmission #1 Project Number S0045 Date submission received 2005-10-13 Status Complete Submission status report Date recommendation issued 2006-03-07 Recommendation and reasons Recommendation Do not list -
Omalizumab
Brand name Xolair Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Asthma, severe persistent Submission type Initial Project Number S0035 Date submission received 2005-04-18 Status Suspended Submission status report Recommendation -
OnabotulinumtoxinA
Brand name Botox Manufacturer Allergan Inc. Indication Neurogenic Detrusor Overactivity Submission type Initial Project Number SR0268 Date submission received 2012-01-31 Call for patient input 2012-01-23 Patient input deadline 2012-02-17 Status Complete Submission status report Date recommendation issued 2012-07-19 Recommendation and reasons Recommendation List with criteria/condition -
Oxybutynin Chloride Gel
Brand name GELNIQUE Manufacturer Watson Pharma Company Indication Bladder, overactive Submission type Initial Project Number S0260 Date submission received 2011-10-25 Call for patient input 2011-10-13 Patient input deadline 2011-11-17 Status Complete Submission status report Date recommendation issued 2012-05-24 Recommendation and reasons Recommendation Do not list -
Oxycodone / naloxone
Brand name Targin Manufacturer Purdue Pharma Indication Pain, Moderate to severe and relief of opioid-induced constipation Submission type Initial Project Number S0219 Date submission received 2010-11-30 Call for patient input 2010-12-02 Patient input deadline 2011-01-21 Status Stopped Submission status report Recommendation -
Oxycodone HCI / naloxone HCI
Brand name Targin Manufacturer Purdue Pharma Indication Pain, Moderate to severe and relief of opioid-induced constipation Submission type Resubmission #1 Project Number S0241 Date submission received 2011-07-05 Status Complete Submission status report Date recommendation issued 2012-01-25 Recommendation and reasons Recommendation Do not list -
Paliperidone
Brand name Invega Manufacturer Janssen-Ortho Inc. Indication Schizophrenia Submission type Initial Project Number S0112 Date submission received 2007-11-01 Status Complete Submission status report Date recommendation issued 2008-05-28 Recommendation and reasons Recommendation Do not list -
Paliperidone palmitate
Brand name Invega Sustenna Manufacturer Janssen-Ortho Inc. Indication Schizophrenia Submission type Initial Project Number S0206 Date submission received 2010-07-09 Call for patient input 2010-06-22 Patient input deadline 2010-07-30 Status Complete Submission status report Date recommendation issued 2011-04-25 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Palonosetron hydrochloride
Brand name Aloxi (injection) Manufacturer Eisai Ltd. Indication Nausea and vomiting (chemotherapy induced) prevention Submission type Initial Project Number SR0293 Date submission received 2012-10-05 Call for patient input 2012-10-05 Patient input deadline 2012-10-26 Status Complete Submission status report Date recommendation issued 2013-05-15 Recommendation and reasons Recommendation Do not list at the submitted price -
Palonosetron hydrochloride
Brand name Aloxi (capsule) Manufacturer Eisai Ltd. Indication Nausea and vomiting (chemotherapy induced) prevention Submission type Initial Project Number SR0294 Date submission received 2012-10-05 Call for patient input 2012-10-05 Patient input deadline 2012-10-26 Status Complete Submission status report Date recommendation issued 2013-04-24 Recommendation and reasons Recommendation Do not list -
Pantoprazole magnesium
Brand name Pantoloc M Manufacturer Altana Pharma Inc. Indication Gastric acid secretion, reduction of Submission type Initial Project Number S0054 Date submission received 2006-03-17 Status Complete Submission status report Date recommendation issued 2006-07-20 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Pegaptanib sodium
Brand name Macugen Manufacturer Pfizer Canada Inc. Indication Macular degeneration, age-related Submission type Initial Project Number S0044 Date submission received 2005-10-20 Status Complete Submission status report Date recommendation issued 2006-05-25 Recommendation and reasons Recommendation Do not list -
Pegfilgrastim
Brand name Neulasta Manufacturer Amgen Canada Inc. Indication Neutropenia Submission type Initial Project Number S0009 Date submission received 2004-03-29 Status Complete Submission status report Date recommendation issued 2004-10-27 Recommendation and reasons Recommendation List with criteria/condition -
Peginterferon alfa-2a and Ribavirin
Brand name Pegasys RBV Manufacturer Hoffman-La Roche Ltd. Indication Hepatitis C, chronic Submission type Initial Project Number S0013 Date submission received 2004-05-14 Status Complete Submission status report Date recommendation issued 2004-10-14 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Pegvisomant
Brand name Somavert Manufacturer Pfizer Canada Inc. Indication acromegaly Submission type Initial Project Number S0050 Date submission received 2006-01-25 Status Complete Submission status report Date recommendation issued 2006-08-02 Recommendation and reasons Recommendation Do not list -
Penciclovir
Brand name Denavir Manufacturer Novartis Consumer Health Care Inc. Indication Herpes labialis (cold sores) Submission type Initial Project Number S0075 Date submission received 2006-09-20 Status Complete Submission status report Date recommendation issued 2007-04-26 Recommendation and reasons Recommendation Do not list -
Perampanel
Brand name Fycompa Manufacturer Eisai Ltd. Indication Epilepsy, partial onset seizures Submission type Pre-NOC Project Number SR0316-000 Date submission received 2013-03-08 (Tentative) Call for patient input 2013-02-21 Patient input deadline 2013-04-01 Status Pending Submission status report Recommendation -
Pirfenidone
Brand name Esbriet Manufacturer InterMune Canada Inc. Indication Pulmonary fibrosis (idiopathic, mild to moderate) Submission type Initial Project Number SR0292 Date submission received 2012-10-05 Call for patient input 2012-10-05 Patient input deadline 2012-10-26 Status Complete Submission status report Date recommendation issued 2013-04-18 Recommendation and reasons Recommendation Do not list -
Plerixafor
Brand name Mozobil Manufacturer Genzyme Canada Inc. Indication Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma Submission type Initial Project Number SR0265 Date submission received 2012-01-24 Call for patient input 2012-01-26 Patient input deadline 2012-02-15 Status Complete Submission status report Date recommendation issued 2012-09-26 Recommendation and reasons Recommendation Do not list -
Posaconazole
Brand name Spriafil Manufacturer Schering-Plough Canada Inc. Indication Aspergillus and Candida infections Submission type Initial Project Number S0097 Date submission received 2007-05-24 Status Complete Submission status report Date recommendation issued 2008-01-30 Recommendation and reasons Recommendation Do not list -
Prasugrel
Brand name Effient Manufacturer Eli Lily Canada Inc. Indication Acute Coronary Syndrome (ACS) Submission type Resubmission #1 Project Number S0263 Date submission received 2011-12-12 Call for patient input 2011-12-16 Patient input deadline 2012-01-16 Status Complete Submission status report Date recommendation issued 2012-06-14 Recommendation and reasons Recommendation Do not list -
Prasugrel hydrochloride
Brand name Effient Manufacturer Eli Lilly Canada Inc. Indication Acute Coronary Syndrome (ACS) Submission type Initial Project Number S0200 Date submission received 2010-05-05 Status Complete Submission status report Date recommendation issued 2011-02-16 Recommendation and reasons Recommendation Do not list -
Pregabalin
Brand name Lyrica Manufacturer Pfizer Canada Inc. Indication diabetic peripheral neuropathy Submission type Resubmission #1 Project Number S0162 Date submission received 2009-03-20 Status Complete Submission status report Date recommendation issued 2009-09-23 Recommendation and reasons Recommendation Do not list -
Pregabalin
Brand name Lyrica Manufacturer Pfizer Canada Inc. Indication Pain, Neuropathic Submission type Initial Project Number S0036 Date submission received 2005-06-27 Status Complete Submission status report Date recommendation issued 2006-01-25 Recommendation and reasons Recommendation Do not list -
Prucalopride
Brand name Resotran Manufacturer Janssen Inc. Indication Constipation, chronic Submission type Initial Project Number SR0266 Date submission received 2012-01-31 Call for patient input 2012-01-17 Patient input deadline 2012-02-22 Status Complete Submission status report Date recommendation issued 2012-07-19 Recommendation and reasons Recommendation Do not list -
Quinagolide hydrochloride
Brand name Norprolac Manufacturer Ferring Pharmaceuticals Indication Hyperprolactinemia Submission type Resubmission #1 Project Number S0046 Date submission received 2005-11-23 Status Complete Submission status report Date recommendation issued 2006-05-17 Recommendation and reasons Recommendation List with criteria/condition -
Quinagolide hydrochloride
Brand name Norprolac Manufacturer Ferring Pharmaceuticals Indication Hyperprolactinemia Submission type Initial Project Number S0026 Date submission received 2004-12-16 Status Complete Submission status report Date recommendation issued 2005-09-28 Recommendation and reasons Recommendation Do not list -
Raltegravir
Brand name Isentress Manufacturer Merck Frosst Canada Ltd. Indication HIV (treatment naïve) Submission type New Indication Project Number S0191 Date submission received 2009-12-04 Status Complete Submission status report Date recommendation issued 2010-06-23 Recommendation and reasons Recommendation Do not list -
Raltegravir
Brand name Isentress Manufacturer Merck Frosst Canada Ltd. Indication HIV Submission type Initial Project Number S0115 Date submission received 2007-11-29 Status Complete Submission status report Date recommendation issued 2008-05-14 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation Summary of CEDAC Discussion Summary of CEDAC Discussion Overview of CDR reports Overview of CDR reports -
Ramipril / felodipine extended release
Brand name Altace Plus Felodipine Manufacturer Sanofi-Aventis Canada Inc. Indication Hypertension Submission type Initial Project Number S0067 Date submission received 2006-06-22 Status Complete Submission status report Date recommendation issued 2006-11-15 Recommendation and reasons Recommendation Do not list -
Ramipril / hydrochlorothiazide
Brand name Altace HCT Manufacturer Sanofi-Aventis Canada Inc. Indication Hypertension Submission type Resubmission #1 Project Number S0095 Date submission received 2007-03-26 Status Complete Submission status report Date recommendation issued 2007-06-14 Recommendation and reasons Recommendation List -
Ramipril / hydrochlorothiazide
Brand name Altace HCT Manufacturer Sanofi –Aventis Canada inc. Indication Hypertension Submission type Initial Project Number S0083 Date submission received 2006-10-26 Status Suspended Submission status report Recommendation -
Ranibizumab
Brand name Lucentis Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Macular edema, diabetic Submission type New Indication Project Number S0253 Date submission received 2011-09-14 Call for patient input 2011-08-31 Patient input deadline 2011-10-05 Status Complete Submission status report Date recommendation issued 2012-03-19 Recommendation and reasons Recommendation List with criteria/condition -
Ranibizumab
Brand name Lucentis Manufacturer Novartis Pharmaceuticals Inc. Indication Macular degeneration, age-related Submission type Initial Project Number S0098 Date submission received 2007-07-12 Status Complete Submission status report Date recommendation issued 2008-03-27 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation Summary of CEDAC Discussion Summary of CEDAC Discussion Overview of CDR reports Overview of CDR reports -
Ranibizumab injection
Brand name Lucentis Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Macular edema, secondary to retinal vein occlusion Submission type Initial Project Number SR0276 Date submission received 2012-04-25 Call for patient input 2012-04-11 Patient input deadline 2012-05-16 Status Complete Submission status report Date recommendation issued 2012-10-18 Recommendation and reasons Recommendation List with criteria/condition -
Rasagiline mesylate
Brand name Azilect Manufacturer Teva Pharmaceuticals Industries Ltd. Indication Parkinson’s disease Submission type Request for Advice Project Number S0161 Date submission received 2009-03-10 Status Complete Submission status report Recommendation -
Rasagiline mesylate
Brand name Azilect Manufacturer Teva Neurosciences Indication Parkinson's disease Submission type Initial Project Number S0073 Date submission received 2006-09-01 Status Complete Submission status report Date recommendation issued 2007-03-28 Recommendation and reasons Recommendation Do not list -
Rilpivirine
Brand name Edurant Manufacturer Janssen Inc. Indication HIV (treatment - naive adult) Submission type Initial Project Number S0243 Date submission received 2011-07-29 Call for patient input 2011-07-15 Patient input deadline 2011-08-22 Status Complete Submission status report Date recommendation issued 2012-02-15 Recommendation and reasons Recommendation List -
Rituximab
Brand name Rituxan Manufacturer Hoffman-La Roche Ltd. Indication Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), remission induction (adults) Submission type New Indication Project Number SR0270 Date submission received 2012-02-24 Call for patient input 2012-02-24 Patient input deadline 2012-03-16 Status Complete Submission status report Date recommendation issued 2012-08-16 Recommendation and reasons Recommendation List with criteria/condition -
Rituximab
Brand name Rituxan Manufacturer Hoffmann-La Roche Limited Indication Arthritis, Rheumatoid Submission type Initial Project Number S0068 Date submission received 2006-06-26 Status Complete Submission status report Date recommendation issued 2007-02-14 Recommendation and reasons Recommendation List with criteria/condition -
Rivaroxaban
Brand name Xarelto Manufacturer Bayer Inc. Indication Thromboembolic events (venous), pulmonary embolism Submission type Initial Project Number SR0327 Date submission received 2013-05-06 Call for patient input 2013-04-05 Patient input deadline 2013-05-27 Patient Input Status Active Submission status report Recommendation -
Rivaroxaban
Brand name Xarelto Manufacturer Bayer Inc. Indication stroke prevention in patients with atrial fibrillation. Submission type Request for Advice Project Number SR0321-00 Date submission received 2013-03-18 Status Active Submission status report Recommendation -
Rivaroxaban
Brand name Xarelto Manufacturer Bayer Inc. Indication Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism Submission type Request for Advice Project Number SF0295 Date submission received 2012-10-27 Status Complete Submission status report Recommendation Record of Advice -
Rivaroxaban
Brand name Xarelto Manufacturer Bayer Inc. Indication Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism Submission type New Indication Project Number SR0271 Date submission received 2012-02-27 Call for patient input 2012-02-16 Patient input deadline 2012-03-20 Status Complete Submission status report Date recommendation issued 2012-08-16 Recommendation and reasons Recommendation List with criteria/condition -
Rivaroxaban
Brand name Xarelto Manufacturer Bayer Inc. Indication Atrial fibrillation, stroke prevention Submission type Pre-NOC Project Number S0257 Date submission received 2011-10-21 Call for patient input 2011-10-18 Patient input deadline 2011-11-09 Status Complete Submission status report Date recommendation issued 2012-04-19 Recommendation and reasons Recommendation List with criteria/condition -
Rivaroxaban
Brand name Xarelto Manufacturer Bayer Inc. Indication Thromboembolism (venous) prevention Submission type Request for Advice Project Number S0239 Date submission received 2011-06-24 Status Complete Submission status report Recommendation -
Rivaroxaban
Brand name Xarelto Manufacturer Bayer Inc. Indication Thromboembolism (venous), prevention Submission type Initial Project Number S0134 Date submission received 2008-05-07 Status Complete Submission status report Date recommendation issued 2008-12-17 Recommendation and reasons Recommendation List with criteria/condition -
Rivastigmine
Brand name Exelon Patch Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Dementia (Alzheimer's type) Submission type Initial Project Number S0123 Date submission received 2007-12-21 Status Complete Submission status report Date recommendation issued 2008-07-23 Recommendation and reasons Recommendation Do not list -
Roflumilast
Brand name Daxas Manufacturer Nycomed Canada Inc. Indication Chronic obstructive pulmonary disease (COPD) Submission type Initial Project Number S0218 Date submission received 2010-11-30 Call for patient input 2010-11-18 Patient input deadline 2011-01-24 Status Complete Submission status report Date recommendation issued 2011-07-27 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Romiplostim
Brand name Nplate Manufacturer Amgen Canada Inc. Indication Chronic immune (idiopathic) thrombocytopenic purpura (ITP) Submission type Initial Project Number S0179 Date submission received 2009-09-29 Status Complete Submission status report Date recommendation issued 2010-05-27 Recommendation and reasons Recommendation Do not list -
Rufinamide
Brand name Banzel Manufacturer Eisai Limited Indication Lennox-Gastaut syndrome; adjunctive treatment of seizures Submission type Initial Project Number S0252 Date submission received 2011-09-20 Call for patient input 2011-09-07 Patient input deadline 2011-10-13 Status Complete Submission status report Date recommendation issued 2012-03-15 Recommendation and reasons Recommendation List with criteria/condition -
Sapropterin dihydrochloride
Brand name Kuvan Manufacturer BioMarin Pharmaceutical Canada Inc. Indication Phenylketonuria (PKU). Submission type Request for Advice Project Number S0236 Date submission received 2011-06-01 Status Complete Submission status report Date advice issued 2011-10-26 Recommendation -
Sapropterin dihydrochloride
Brand name Kuvan Manufacturer BioMarin Pharmaceutical Canada Inc. Indication Phenylketonuria (PKU). Submission type Initial Project Number S0205 Date submission received 2010-07-08 Call for patient input 2010-07-05 Patient input deadline 2010-07-29 Status Complete Submission status report Date recommendation issued 2011-01-26 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Saxagliptin
Brand name Onglyza Manufacturer Bristol-Myers Squibb / AstraZeneca Canada Inc. Indication Diabetes mellitus (Type 2) Submission type Pre-NOC Project Number SR0329 Date submission received 2013-05-09 Call for patient input 2013-05-09 Patient input deadline 2013-05-31 Patient Input Status Active Recommendation -
Saxagliptin
Brand name Onglyza Manufacturer Bristol-Myers Squibb / AstraZeneca Canada Inc. Indication Diabetes mellitus (Type 2) Submission type Resubmission #1 Project Number SR0280 Date submission received 2012-05-28 Call for patient input 2012-05-28 Patient input deadline 2012-06-18 Status Withdrawn Submission status report Recommendation -
Saxagliptin
Brand name Onglyza Manufacturer Bristol-Myers Squibb Canada Indication Diabetes mellitus (Type 2) Submission type Initial Project Number S0185 Date submission received 2009-11-09 Status Complete Submission status report Date recommendation issued 2010-06-17 Recommendation and reasons Recommendation Do not list -
Sildenafil citrate
Brand name Revatio Manufacturer Pfizer Canada Inc. Indication Pulmonary arterial hypertension (WHO class II and III) Submission type Initial Project Number S0076 Date submission received 2006-09-20 Status Complete Submission status report Date recommendation issued 2007-02-14 Recommendation and reasons Recommendation List in a similar manner -
Silodosin
Brand name RAPAFLO Manufacturer Watson Pharma Company Indication Prostatic Hyperplasia, benign Submission type Initial Project Number S0261 Date submission received 2011-10-25 Call for patient input 2011-10-13 Patient input deadline 2011-11-17 Status Complete Submission status report Date recommendation issued 2012-04-19 Recommendation and reasons Recommendation Do not list -
Sitagliptin phosphate
Brand name Januvia Manufacturer Merck Frosst Canada Ltd. Indication Diabetes mellitus (Type 2) Submission type Resubmission #1 Project Number S0181 Date submission received 2009-10-29 Status Complete Submission status report Date recommendation issued 2010-06-23 Recommendation and reasons Recommendation List with criteria/condition -
Sitagliptin phosphate
Brand name Januvia Manufacturer Merck Frosst Canada Ltd. Indication Diabetes mellitus (Type 2) Submission type Initial Project Number S0122 Date submission received 2007-12-20 Status Complete Submission status report Date recommendation issued 2008-06-18 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation Summary of CEDAC Discussion Summary of CEDAC Discussion Overview of CDR reports Overview of CDR reports -
Sitagliptin phosphate monohydrate / metformin hydrochloride
Brand name Janumet Manufacturer Merck Frosst Canada Ltd. Indication Diabetes mellitus (Type 2) Submission type Initial Project Number S0182 Date submission received 2009-11-04 Status Complete Submission status report Date recommendation issued 2010-06-23 Recommendation and reasons Recommendation List with criteria/condition -
Sitaxsentan sodium
Brand name Thelin Manufacturer Encysive Canada Inc. Indication Pulmonary arterial hypertension (WHO class II and III) Submission type Resubmission #1 Project Number S0132 Date submission received 2008-05-05 Status Complete Submission status report Date recommendation issued 2009-01-28 Recommendation and reasons Recommendation Do not list -
Sitaxsentan sodium
Brand name Thelin Manufacturer Encysive Canada Inc. Indication Pulmonary arterial hypertension (WHO class II and III) Submission type Initial Project Number S0099 Date submission received 2007-06-22 Status Complete Submission status report Date recommendation issued 2008-01-30 Recommendation and reasons Recommendation Do not list -
Sodium oxybate
Brand name Xyrem Manufacturer Valeant Canada Ltd. Indication Narcolepsy Submission type Resubmission #1 Project Number S0141 Date submission received 2008-07-09 Status Complete Submission status report Date recommendation issued 2009-01-28 Recommendation and reasons Recommendation Do not list -
Sodium oxybate
Brand name Xyrem Manufacturer Valeant Canada Ltd. Indication Narcolepsy Submission type Initial Project Number S0107 Date submission received 2007-08-29 Status Withdrawn Submission status report Recommendation -
Solifenacin succinate
Brand name Vesicare Manufacturer Astellas Pharma Canada Inc. Indication Bladder, overactive Submission type Resubmission #1 Project Number S0155 Date submission received 2009-01-05 Status Complete Submission status report Date recommendation issued 2009-06-17 Recommendation and reasons Recommendation List with criteria/condition -
Solifenacin succinate
Brand name Vesicare Manufacturer Astellas Pharma Canada Inc. Indication Bladder, overactive Submission type Initial Project Number S0070 Date submission received 2006-07-24 Status Complete Submission status report Date recommendation issued 2007-01-24 Recommendation and reasons Recommendation Do not list -
Somatropin (rDNA origin)
Brand name Omnitrope Manufacturer Sandoz Canada Inc. Indication Growth hormone deficiency in children and adults Submission type Initial Project Number S0167 Date submission received 2009-06-12 Status Complete Submission status report Date advice issued 2009-12-16 Advice - SEB Recommendation -
Sorafenib tablets
Brand name Nexavar Manufacturer Bayer Inc. Indication Cancer, Renal cell carcinoma Submission type Initial Project Number S0071 Date submission received 2006-07-31 Status Complete Submission status report Date recommendation issued 2007-02-28 Recommendation and reasons Recommendation Do not list -
Sunitinib
Brand name Sutent Manufacturer Pfizer Canada Inc. Indication Gastrointestinal stromal tumour (GIST) Submission type Initial Project Number S0069 Date submission received 2006-07-20 Status Complete Submission status report Date recommendation issued 2007-03-28 Recommendation and reasons Recommendation List with criteria/condition -
Sunitinib malate
Brand name Sutent Manufacturer Pfizer Canada Inc. Indication Cancer, Metastatic renal cell carcinoma Submission type Resubmission #1 Project Number S0077 Date submission received 2006-09-20 Status Complete Submission status report Date recommendation issued 2007-04-26 Recommendation and reasons Recommendation Do not list -
Tadalafil
Brand name Adcirca Manufacturer Eli Lilly Canada Inc. Indication Pulmonary arterial hypertension Submission type Initial Project Number S0197 Date submission received 2010-02-05 Status Complete Submission status report Date recommendation issued 2010-07-15 Recommendation and reasons Recommendation List with criteria/condition -
Tapentadol
Brand name Nucynta CR Manufacturer Janssen Inc. Indication Pain, moderate to moderately severe Submission type Initial Project Number S0224 Date submission received 2011-02-01 Call for patient input 2011-01-20 Patient input deadline 2011-02-24 Status Complete Submission status report Date recommendation issued 2011-09-28 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Telaprevir
Brand name Incivek Manufacturer Vertex Pharmaceuticals Canada Inc. Indication Hepatitis C infection, chronic Submission type Request for Advice Project Number SF0311 Date submission received 2013-02-19 Status Active Submission status report Recommendation -
Telaprevir
Brand name Incivek Manufacturer Vertex Pharmaceuticals Canada Inc. Indication Hepatitis C, chronic Submission type Request for Advice Project Number SR0305 Date submission received 2013-01-02 Status Active Submission status report Recommendation -
Telaprevir
Brand name Incivek Manufacturer Vertex Pharmaceuticals Inc. Indication Hepatitis C infection (genotype 1), Chronic Submission type Initial Project Number S0249 Date submission received 2011-08-23 Call for patient input 2011-08-16 Patient input deadline 2011-09-14 Status Complete Submission status report Date recommendation issued 2012-02-15 Recommendation and reasons Recommendation List with criteria/condition -
Telbivudine
Brand name Sebivo Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Hepatitis B (chronic) Submission type Initial Project Number S0088 Date submission received 2006-12-04 Status Complete Submission status report Date recommendation issued 2007-09-26 Recommendation and reasons Recommendation Do not list -
Telmisartan / Amlodipine
Brand name Twynsta Manufacturer Boehringer Ingelheim (Canada) Ltd Indication Hypertension, Essential Submission type Pre-NOC Project Number S0207 Date submission received 2010-07-09 Call for patient input 2010-07-09 Patient input deadline 2010-07-30 Status Rejected Submission status report Recommendation -
Telmisartan / Amlodipine
Brand name Twynsta Manufacturer Boehringer Ingelheim Canada Indication Hypertension, Essential Submission type Initial Project Number S0245 Date submission received 2011-08-23 Call for patient input 2011-08-09 Patient input deadline 2011-09-14 Status Complete Submission status report Date recommendation issued 2011-12-16 Recommendation and reasons Recommendation List Plain language recommendation Plain language recommendation -
Tenofovir disoproxil fumarate
Brand name Viread Manufacturer Gilead Sciences Canada Inc. Indication Hepatitis B (chronic) Submission type New Indication Project Number S0148 Date submission received 2008-10-02 Status Complete Submission status report Date recommendation issued 2009-03-18 Recommendation and reasons Recommendation List with criteria/condition -
Tenofovir disoproxil fumarate
Brand name Viread Manufacturer Gilead Sciences Canada Inc. Indication HIV infection Submission type Request for Advice Project Number S0139 Date submission received 2008-07-07 Status Complete Submission status report Recommendation -
Tenofovir disoproxil fumarate
Brand name Viread Manufacturer Gilead Sciences Canada Inc. Indication HIV infection Submission type Resubmission #1 Project Number S0040 Date submission received 2005-08-11 Status Complete Submission status report Date recommendation issued 2006-03-15 Recommendation and reasons Recommendation List with criteria/condition -
Tenofovir disoproxil fumarate
Brand name Viread Manufacturer Gilead Sciences Canada Inc. Indication HIV infection Submission type Initial Project Number S0008 Date submission received 2004-02-23 Status Complete Submission status report Date recommendation issued 2004-08-25 Recommendation and reasons Recommendation Do not list -
Teriparatide (rDNA origin) injection
Brand name Forteo Manufacturer Eli Lilly Canada Inc. Indication Osteoporosis (in women), Severe Submission type ACP Submission Project Number S0180 Date submission received 2009-10-23 Status Complete Submission status report Date recommendation issued 2010-03-17 Recommendation and reasons Recommendation Do not list -
Teriparatide (rDNA origin) injection
Brand name Forteo Manufacturer Eli Lilly Canada Inc. Indication Osteoporosis Submission type Resubmission #3 Project Number S0169 Date submission received 2009-06-12 Status Withdrawn Submission status report Recommendation -
Teriparatide (rDNA origin) injection
Brand name Forteo Manufacturer Eli Lilly Canada Inc. Indication Osteoporosis, glucocorticoid induced Submission type New Indication Project Number S0152 Date submission received 2008-12-18 Status Complete Submission status report Date recommendation issued 2009-07-22 Recommendation and reasons Recommendation Do not list -
Teriparatide (rDNA origin) injection
Brand name Forteo Manufacturer Eli Lilly Canada Inc. Indication Osteoporosis Submission type Resubmission #2 Project Number S0157 Date submission received 2008-12-18 Status Withdrawn Submission status report Recommendation -
Teriparatide (rDNA origin) injection
Brand name Forteo Manufacturer Eli Lilly Canada Inc. Indication Osteoporosis Submission type Resubmission #1 Project Number S0065 Date submission received 2006-05-29 Status Withdrawn Submission status report Recommendation -
Teriparatide (rDNA origin) injection
Brand name Forteo Manufacturer Eli Lilly Canada Inc. Indication Osteoporosis Submission type Initial Project Number S0015 Date submission received 2004-06-08 Status Complete Submission status report Date recommendation issued 2004-12-22 Recommendation and reasons Recommendation Do not list -
Ticagrelor
Brand name Brilinta Manufacturer AstraZeneca Canada Inc Indication Thrombotic events in Acute Coronary Syndromes, Prevention Submission type Initial Project Number S0234 Date submission received 2011-06-01 Call for patient input 2011-05-17 Patient input deadline 2011-06-22 Status Complete Submission status report Date recommendation issued 2011-12-16 Recommendation and reasons Recommendation Do not list Plain language recommendation Plain language recommendation -
Ticagrelor
Brand name Brilinta Manufacturer AstraZeneca Canada Inc Indication Acute Coronary Syndromes (ACS) Submission type Pre-NOC - Initial Project Number S0203 Date submission received 2010-06-08 Call for patient input 2010-06-08 Patient input deadline 2010-06-30 Status Stopped Submission status report Recommendation -
Tipranavir
Brand name Aptivus Manufacturer Boehringer Ingelheim (Canada) Inc. Indication HIV infection Submission type Initial Project Number S0047 Date submission received 2005-12-15 Status Complete Submission status report Date recommendation issued 2006-05-17 Recommendation and reasons Recommendation List with criteria/condition -
Tocilizumab
Brand name Actemra Manufacturer Hoffman-La Roche Ltd. Indication Arthritis, juvenile idiopathic Submission type New Indication Project Number S0267 Date submission received 2012-01-30 Call for patient input 2012-01-30 Patient input deadline 2012-02-17 Status Complete Submission status report Date recommendation issued 2012-07-19 Recommendation and reasons Recommendation List with criteria/condition -
Tocilizumab
Brand name Actemra Manufacturer Hoffmann-La Roche Limited Indication Arthritis, Rheumatoid Submission type Initial Project Number S0201 Date submission received 2010-05-27 Call for patient input 2010-05-21 Patient input deadline 2010-06-17 Status Complete Submission status report Date recommendation issued 2010-11-17 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Tolvaptan
Brand name Samsca Manufacturer Otsuka Canada Pharmaceutical Inc. Indication Hyponatremia, non-hypovolemic Submission type Initial Project Number SR0283 Date submission received 2012-07-03 Call for patient input 2012-07-03 Patient input deadline 2012-07-24 Status Complete Submission status report Date recommendation issued 2013-02-13 Recommendation and reasons Recommendation Do not list -
Tramadol hydrochloride
Brand name Tridural Manufacturer Labopharm Inc. Indication Pain Submission type Initial Project Number S0117 Date submission received 2007-11-29 Status Complete Submission status report Date recommendation issued 2008-04-17 Recommendation and reasons Recommendation Do not list -
Tramadol hydrochloride
Brand name Ralivia Manufacturer Biovail Pharmaceuticals Canada Indication Pain Submission type Initial Project Number S0110 Date submission received 2007-10-29 Status Complete Submission status report Date recommendation issued 2008-06-25 Recommendation and reasons Recommendation Do not list -
Tramadol hydrochloride
Brand name Zytram XL Manufacturer Purdue Pharma Indication Pain, acute Submission type Resubmission #1 Project Number S0093 Date submission received 2007-03-15 Status Complete Submission status report Date recommendation issued 2007-09-26 Recommendation and reasons Recommendation Do not list -
Tramadol hydrochloride
Brand name Zytram XL Manufacturer Purdue Pharma Indication Pain, acute Submission type Initial Project Number S0086 Date submission received 2006-11-03 Status Withdrawn Submission status report Recommendation -
Tramadol hydrochloride / acetaminophen
Brand name Tramacet Manufacturer Janssen-Ortho Inc. Indication Acute pain Submission type Initial Project Number S0079 Date submission received 2006-10-02 Status Complete Submission status report Date recommendation issued 2007-05-17 Recommendation and reasons Recommendation Do not list -
Travoprost and timolol maleate
Brand name DuoTrav Manufacturer Alcon Canada Inc. Indication Glaucoma Submission type Initial Project Number S0057 Date submission received 2006-03-24 Status Complete Submission status report Date recommendation issued 2006-08-24 Recommendation and reasons Recommendation List with criteria/condition -
Treprostinil sodium
Brand name Remodulin Manufacturer Northern Therapeutics Inc. Indication Pulmonary arterial hypertension (NYHA Class III and IV patients) Submission type Resubmission #1 Project Number S0052 Date submission received 2006-02-24 Status Complete Submission status report Date recommendation issued 2006-07-20 Recommendation and reasons Recommendation List with criteria/condition -
Treprostinil sodium
Brand name Remodulin Manufacturer Northern Therapeutics Inc. Indication Pulmonary arterial hypertension (NYHA Class III and IV patients) Submission type Initial Project Number S0011 Date submission received 2004-07-14 Status Complete Submission status report Date recommendation issued 2004-11-17 Recommendation and reasons Recommendation Do not list -
Triptorelin pamoate
Brand name Trelstar Manufacturer Watson Laboratories Inc. Indication Cancer, prostate Submission type Initial Project Number S0051 Date submission received 2006-02-27 Status Complete Submission status report Date recommendation issued 2006-07-20 Recommendation and reasons Recommendation List in a similar manner to other drugs in class -
Trospium chloride
Brand name Trosec Manufacturer Oryx Pharmaceuticals Inc. Indication Bladder, overactive Submission type Initial Project Number S0055 Date submission received 2006-03-24 Status Complete Submission status report Date recommendation issued 2006-08-24 Recommendation and reasons Recommendation List with criteria/condition -
Ulipristal acetate
Brand name Fibristal Manufacturer Watson Pharma Company Indication Uterine fibroids (signs and symptoms) Submission type Pre-NOC Project Number SR0326 Date submission received 2013-04-18 (Tentative) Call for patient input 2013-04-15 Patient input deadline 2013-05-09 Status Active Submission status report Recommendation -
Ustekinumab
Brand name Stelara Manufacturer Janssen-Ortho Inc. Indication Psoriasis Submission type Initial Project Number S0156 Date submission received 2009-01-07 Status Complete Submission status report Date recommendation issued 2009-06-17 Recommendation and reasons Recommendation List with criteria/condition -
Varenicline tartrate
Brand name Champix Manufacturer Pfizer Canada Inc. Indication Smoking-cessation Submission type Initial Project Number S0094 Date submission received 2007-03-21 Status Complete Submission status report Date recommendation issued 2007-08-16 Recommendation and reasons Recommendation List with criteria/condition -
Velaglucerase alfa
Brand name VPRIV Manufacturer Shire Human Genetic Therapies Indication Gaucher Disease Submission type Initial Project Number S0215 Date submission received 2010-10-28 Call for patient input 2010-10-29 Patient input deadline 2010-11-18 Status Complete Submission status report Date recommendation issued 2011-04-25 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Voriconazole
Brand name VFEND Manufacturer Pfizer Canada Inc. Indication Candidemia Submission type Resubmission #2 Project Number S0056 Date submission received 2006-03-24 Status Complete Submission status report Date recommendation issued 2006-10-25 Recommendation and reasons Recommendation List with criteria/condition -
Voriconazole
Brand name VFEND Manufacturer Pfizer Canada Inc. Indication Aspergillosis, Invasive Submission type Resubmission #1 Project Number S0023 Date submission received 2004-10-25 Status Complete Submission status report Date recommendation issued 2005-04-14 Recommendation and reasons Recommendation List with criteria/condition -
Voriconazole
Brand name VFEND Manufacturer Pfizer Canada Inc. Indication Aspergillosis, Invasive Submission type Initial Project Number S0020 Date submission received 2004-08-24 Status Withdrawn Submission status report Recommendation -
Ziprasidone hydrochloride
Brand name Zeldox Manufacturer Pfizer Canada Inc. Indication Schizophrenia and related psychotic disorders Submission type Initial Project Number S0124 Date submission received 2008-01-10 Status Complete Submission status report Date recommendation issued 2008-08-14 Recommendation and reasons Recommendation List with criteria/condition -
Zoledronic acid
Brand name Aclasta Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Osteoporosis (postmenopausal women) Submission type Request for Advice Project Number S0242 Date submission received 2011-07-20 Status Complete Submission status report Date recommendation issued 2011-11-16 Recommendation and reasons Recommendation List with criteria/condition Plain language recommendation Plain language recommendation -
Zoledronic acid
Brand name Aclasta Manufacturer Novartis Pharmaceuticals Canada Inc. Indication Osteoporosis, postmenopausal women Submission type Initial Project Number S0114 Date submission received 2007-11-29 Status Complete Submission status report Date recommendation issued 2008-06-25 Recommendation and reasons Recommendation List with criteria/condition -
Zolpidem tartrate
Brand name Sublinox Manufacturer Meda Valeant Pharma Canada Inc. Indication Insomnia, short-term treatment Submission type Initial Project Number SR0314 Date submission received 2013-03-07 Call for patient input 2013-03-07 Patient input deadline 2013-03-28 Status Pending Submission status report Recommendation